Mylan Speciality Lp Drug Patent Portfolio
Mylan Speciality Lp owns 11 orange book drugs protected by 41 US patents with Sfrowasa having the least patent protection, holding only 1 patent. And Tobi Podhaler with maximum patent protection, holding 14 patents. Given below is the list of Mylan Speciality Lp's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9265720 | Pharmaceutical formulations useful in the treatment of insomnia | 25 Feb, 2031 | Active |
| US10207066 | Aerosolization apparatus with capsule puncture alignment guide | 04 Nov, 2030 | Active |
| US8869794 | Aerosolization apparatus with capsule puncturing member | 12 Sep, 2028 | Active |
| US8071073 | Compositions comprising azelastine and methods of use thereof | 04 Jun, 2028 | Active |
| US7645801 | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) | 24 Jul, 2027 | Active |
| US9597281 | Pharmaceutical formulations useful in the treatment of insomnia | 06 Apr, 2027 | Active |
| US8168620 | Combination of azelastine and steroids | 24 Aug, 2026 | Active |
| US8168620 | Combination of azelastine and steroids | 24 Feb, 2026 | Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof | 22 Nov, 2025 | Active |
| US9919050 | Compositions comprising azelastine | 22 Nov, 2025 | Active |
| US7559325 | Aerosolization apparatus with air inlet shield | 27 Oct, 2025 | Active |
| US7449012 | Automatic injector | 11 Sep, 2025 | Active |
| US7794432 | Automatic injector with kickback attenuation | 11 Sep, 2025 | Active |
| US8048035 | Automatic injector with needle cover | 11 Sep, 2025 | Active |
| US8870827 | Automatic injector | 11 Sep, 2025 | Active |
| US9586010 | Automatic injector with needle cover | 11 Sep, 2025 | Active |
| US8664187 | Methods of treatment of endobronchial infections | 20 Jun, 2025 | Active |
| US11484671 | Aerosolization apparatus with capsule puncture alignment guide | 07 Nov, 2024 | Expired |
| US8069851 | Aeorosolization apparatus with air inlet shield | 24 Sep, 2024 | Expired |
| USRE47526 | Aerosolization apparatus with air inlet shield | 09 Apr, 2024 | Expired |
| US8163723 | Combination of azelastine and steroids | 29 Feb, 2024 | Expired |
| US7516741 | Aerosolization apparatus with feedback mechanism | 11 Jan, 2024 | Expired |
| US9259428 | Combination of azelastine and fluticasone for nasal administration | 13 Dec, 2023 | Expired |
| US8163723 | Combination of azelastine and steroids | 29 Aug, 2023 | Expired |
| US9259428 | Combination of azelastine and fluticasone for nasal administration | 13 Jun, 2023 | Expired |
| US9901585 | Combination of azelastine and fluticasone for nasal administration | 13 Jun, 2023 | Expired |
| US7368102 | Pulmonary delivery of aminoglycosides | 19 Dec, 2022 | Expired |
| US8715623 | Pulmonary delivery of aminoglycoside | 19 Dec, 2022 | Expired |
| US9421166 | Pulmonary delivery of aminoglycoside | 19 Dec, 2022 | Expired |
| US7198801 | Formulations for transdermal or transmucosal application | 25 Jun, 2022 | Expired |
| US7470433 | Formulations for transdermal or transmucosal application | 03 Aug, 2021 | Expired |
| US7097827 | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments | 27 Jun, 2021 | Expired |
| US7442388 | Phospholipid-based powders for drug delivery | 10 May, 2020 | Expired |
| US8349294 | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use | 10 May, 2020 | Expired |
| US6761910 | Pharmaceutical composition for the treatment of acute disorders | 24 Sep, 2019 | Expired |
| US8512747 | Pharmaceutical composition for the treatment of acute disorders | 24 Sep, 2019 | Expired |
| US5980867 | Flunisolide aerosol formulations | 06 Jul, 2018 | Expired |
| US5886039 | Method and composition for treating erectile dysfunction | 23 Mar, 2016 | Expired |
| US5776433 | Flunisolide aerosol formulations | 07 Jul, 2015 | Expired |
| US5508269 | Aminoglycoside formulation for aerosolization | 19 Oct, 2014 | Expired |
| US5474535 | Dosage and inserter for treatment of erectile dysfunction | 12 Dec, 2012 | Expired |
Latest Legal Activities on Mylan Speciality Lp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mylan Speciality Lp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 03 Jun, 2024 | US8168620 (Litigated) |
|
Expire Patent
Critical
| 27 May, 2024 | US8163723 (Litigated) |
| Court Processing Terminated | 17 Apr, 2024 | US7516741 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Apr, 2024 | US9421166 |
|
Expire Patent
Critical
| 25 Mar, 2024 | US9259428 (Litigated) |
| Court Processing Terminated | 01 Mar, 2024 | US7097827 |
| Court Processing Terminated | 28 Feb, 2024 | US7442388 |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Dec, 2023 | US8168620 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 11 Dec, 2023 | US8163723 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 09 Oct, 2023 | US9259428 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 May, 2023 | US8071073 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Apr, 2023 | US8048035 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Apr, 2023 | US8048035 |
|
Recordation of Patent Grant Mailed
Critical
| 01 Nov, 2022 | US11484671 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 01 Nov, 2022 | US11484671 |
Mylan Speciality Lp's Drug Patent Litigations
Mylan Speciality Lp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 23, 2008, against patent number US7645801. The petitioner , challenged the validity of this patent, with Bala VENKATARAMAN et al as the respondent. Click below to track the latest information on how companies are challenging Mylan Speciality Lp's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8163723 | January, 2020 |
Terminated-Denied
(31 Jul, 2020)
| Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US8168620 | January, 2020 |
Terminated-Denied
(31 Jul, 2020)
| Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US9259428 | January, 2020 |
Terminated-Denied
(31 Jul, 2020)
| Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US9901585 | January, 2020 |
Terminated-Denied
(31 Jul, 2020)
| Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US10207066 | October, 2016 |
Decision
(18 Sep, 2018)
| Michael John Dunkley et al | |
| US8168620 | February, 2017 |
Terminated-Settled
(21 May, 2018)
| Cipla Limited | Argentum Pharmaceuticals LLC |
| US8071073 | May, 2014 |
Terminated-Denied
(29 Jul, 2014)
| Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
| US10207066 | May, 2009 |
Decision
(23 Dec, 2011)
| Michael John Dunkley et al | |
| US7645801 | April, 2008 |
Decision
(08 Dec, 2008)
| Bala VENKATARAMAN et al | |
Mylan Speciality Lp Drug Patents' Oppositions Filed in EPO
Mylan Speciality Lp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 14, 2010, by Glaxo Group Limited. This opposition was filed on patent number EP03738280A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP10155967A | Jan, 2021 | Keilitz Haines & Partner Patentanwälte PartGmbB | Granted and Under Opposition |
| EP10155967A | Apr, 2020 | ALK-ABELLO A/S | Granted and Under Opposition |
| EP05783727A | Nov, 2016 | ALK-ABELLO A/S | Revoked |
| EP05783727A | Nov, 2016 | Merck Patent GmbH | Revoked |
| EP05783727A | Oct, 2016 | Meridian Medical Technologies, Inc. | Revoked |
| EP09173753A | Jul, 2016 | Merck Patent GmbH | Patent maintained as amended |
| EP09075100A | Apr, 2016 | Sanovel IIaç San. ve Tic. A.S. | Revoked |
| EP10194414A | Feb, 2015 | Feldmeier, Jürgen | Revoked |
| EP10194414A | Nov, 2014 | ALK-ABELLO A/S | Revoked |
| EP09075101A | Oct, 2014 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Revoked |
| EP09075101A | Oct, 2014 | Sanovel IIaç San. ve Tic. A.S. | Revoked |
| EP04759324A | Dec, 2012 | NORTON HEALTHCARE LIMITED | Patent maintained as amended |
| EP03738280A | Jan, 2010 | Glaxo Group Limited | Revoked |
Mylan Speciality Lp's Family Patents
Mylan Speciality Lp Drug List
Given below is the complete list of Mylan Speciality Lp's drugs and the patents protecting them.
1. Aerospan Hfa
Aerospan Hfa is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5980867 | Flunisolide aerosol formulations |
06 Jul, 2018
(6 years ago)
| Expired |
| US5776433 | Flunisolide aerosol formulations |
07 Jul, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aerospan Hfa's drug page
2. Astepro
Astepro is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071073 | Compositions comprising azelastine and methods of use thereof |
04 Jun, 2028
(3 years from now)
| Active |
| US8518919 | Compositions comprising azelastine and methods of use thereof |
22 Nov, 2025
(1 year, 6 days from now)
| Active |
| US9919050 | Compositions comprising azelastine |
22 Nov, 2025
(1 year, 6 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Astepro's drug page
3. Dymista
Dymista is protected by 7 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8168620
(Pediatric)
| Combination of azelastine and steroids |
24 Aug, 2026
(1 year, 9 months from now)
| Active |
| US8168620 | Combination of azelastine and steroids |
24 Feb, 2026
(1 year, 3 months from now)
| Active |
| US8163723
(Pediatric)
| Combination of azelastine and steroids |
29 Feb, 2024
(8 months ago)
| Expired |
| US9259428
(Pediatric)
| Combination of azelastine and fluticasone for nasal administration |
13 Dec, 2023
(11 months ago)
| Expired |
| US8163723 | Combination of azelastine and steroids |
29 Aug, 2023
(1 year, 2 months ago)
| Expired |
| US9259428 | Combination of azelastine and fluticasone for nasal administration |
13 Jun, 2023
(1 year, 5 months ago)
| Expired |
| US9901585 | Combination of azelastine and fluticasone for nasal administration |
13 Jun, 2023
(1 year, 5 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dymista's drug page
4. Edluar
Edluar is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9265720 | Pharmaceutical formulations useful in the treatment of insomnia |
25 Feb, 2031
(6 years from now)
| Active |
| US9597281 | Pharmaceutical formulations useful in the treatment of insomnia |
06 Apr, 2027
(2 years from now)
| Active |
| US6761910 | Pharmaceutical composition for the treatment of acute disorders |
24 Sep, 2019
(5 years ago)
| Expired |
| US8512747 | Pharmaceutical composition for the treatment of acute disorders |
24 Sep, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Edluar's drug page
5. Elestrin
Elestrin is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7198801 | Formulations for transdermal or transmucosal application |
25 Jun, 2022
(2 years ago)
| Expired |
| US7470433 | Formulations for transdermal or transmucosal application |
03 Aug, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Elestrin's drug page
Explore Our Curated Drug Screens
6. Epipen
Epipen is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7449012 | Automatic injector |
11 Sep, 2025
(9 months from now)
| Active |
| US7794432 | Automatic injector with kickback attenuation |
11 Sep, 2025
(9 months from now)
| Active |
| US8048035 | Automatic injector with needle cover |
11 Sep, 2025
(9 months from now)
| Active |
| US8870827 | Automatic injector |
11 Sep, 2025
(9 months from now)
| Active |
| US9586010 | Automatic injector with needle cover |
11 Sep, 2025
(9 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epipen's drug page
7. Epipen Jr.
Epipen Jr. is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7449012 | Automatic injector |
11 Sep, 2025
(9 months from now)
| Active |
| US7794432 | Automatic injector with kickback attenuation |
11 Sep, 2025
(9 months from now)
| Active |
| US8048035 | Automatic injector with needle cover |
11 Sep, 2025
(9 months from now)
| Active |
| US8870827 | Automatic injector |
11 Sep, 2025
(9 months from now)
| Active |
| US9586010 | Automatic injector with needle cover |
11 Sep, 2025
(9 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epipen Jr.'s drug page
8. Muse
Muse is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5886039 | Method and composition for treating erectile dysfunction |
23 Mar, 2016
(8 years ago)
| Expired |
| US5474535 | Dosage and inserter for treatment of erectile dysfunction |
12 Dec, 2012
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Muse's drug page
9. Sfrowasa
Sfrowasa is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7645801 | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
24 Jul, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sfrowasa's drug page
10. Tobi
Tobi is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5508269 | Aminoglycoside formulation for aerosolization |
19 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tobi's drug page
11. Tobi Podhaler
Tobi Podhaler is protected by 14 patents, out of which 10 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10207066 | Aerosolization apparatus with capsule puncture alignment guide |
04 Nov, 2030
(5 years from now)
| Active |
| US8869794 | Aerosolization apparatus with capsule puncturing member |
12 Sep, 2028
(3 years from now)
| Active |
| US7559325 | Aerosolization apparatus with air inlet shield |
27 Oct, 2025
(11 months from now)
| Active |
| US8664187 | Methods of treatment of endobronchial infections |
20 Jun, 2025
(7 months from now)
| Active |
| US11484671 | Aerosolization apparatus with capsule puncture alignment guide |
07 Nov, 2024
(8 days ago)
| Expired |
| US8069851 | Aeorosolization apparatus with air inlet shield |
24 Sep, 2024
(a month ago)
| Expired |
| USRE47526 | Aerosolization apparatus with air inlet shield |
09 Apr, 2024
(7 months ago)
| Expired |
| US7516741 | Aerosolization apparatus with feedback mechanism |
11 Jan, 2024
(10 months ago)
| Expired |
| US7368102 | Pulmonary delivery of aminoglycosides |
19 Dec, 2022
(1 year, 10 months ago)
| Expired |
| US8715623 | Pulmonary delivery of aminoglycoside |
19 Dec, 2022
(1 year, 10 months ago)
| Expired |
| US9421166 | Pulmonary delivery of aminoglycoside |
19 Dec, 2022
(1 year, 10 months ago)
| Expired |
| US7097827 | Devices, compositions and methods for the pulmonary delivery of aerosolized medicaments |
27 Jun, 2021
(3 years ago)
| Expired |
| US7442388 | Phospholipid-based powders for drug delivery |
10 May, 2020
(4 years ago)
| Expired |
| US8349294 | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
10 May, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tobi Podhaler's drug page